S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com -- Halozyme Therapeutics , Inc. (NASDAQ:HALO) saw its shares jump 7.4% after the biotechnology company reported first-quarter earnings and revenue that surpassed analyst expectations and raised its full-year outlook.
Halozyme posted adjusted earnings per share of $1.11 for Q1, beating the analyst consensus of $0.98. Revenue came in at $265 million, topping estimates of $229.29 million and representing a 35% increase YoY.
The company’s strong performance was driven by a 39% YoY rise in royalty revenue to $168.2 million, primarily due to increased sales of VYVGART Hytrulo, DARZALEX SC, and Phesgo.
"2025 is off to a strong start with our current three blockbuster brands continuing to demonstrate strong growth," said Dr. Helen Torley, CEO of Halozyme. She noted that recently launched products are just beginning to contribute as partners focus on expanding coverage and reimbursement.
Halozyme raised its 2025 guidance, now expecting total revenue of $1.2 billion to $1.28 billion, up from its previous forecast of $1.15 billion to $1.225 billion. The company also increased its adjusted EPS outlook to $5.30-$5.70, compared to the prior $4.95-$5.35 range.
Additionally, Halozyme announced a new $250 million share repurchase program, signaling confidence in its financial position and growth prospects.
The company’s pipeline continues to advance, with two products in Phase 3 trials and progress reported on other development programs during the quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.